YTHDF1 and colorectal carcinoma: Targeting YTHDF1 or its downstream effector NOTCH1 mitigates chemoresistance in CRC, and combining YTHDF1 inhibition with chemotherapy represents a promising strategy to improve treatment efficacy (Fig. 8i).